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Autooxidation of anthralin by air can be enhanced by 
irradiation with U V or visible radiation, by increase in 
temperature or pH and by the presence of zinc ions [14]. 
At the biological level anthralin readily binds to serum 
albumin and epidermal protein and is then oxidized [10]. 
Oxidation intermediates, such as anthralin or anthralin-
free radicals, may be responsible for the biological effect. 
Therefore, anthralin should be stable in therapeutical 
prescriptions, but oxidation in vivo should not be pre-
vented. Anthralin has dual solubility characteristics due 
to the hydrophilic hydroxyl and carbonyl groups and the 
lipophilic 10-methylene group [1]. It is, however, rela-
tively unstable in aqueous or alcoholic solutions [7, 11], 
but relatively stable in white soft paraffin [8]. 
Liposomes, consisting of phospholipids and forming 
vesicles in aqueous solutions, have been shown to be 
ideal carriers and penetration enhancers for some topical 
dermatological drugs, e.g. glucocorticoids and antimy-
cotics [3, 4]. We therefore tested anthralin stability in 
phospholipid liposomes. Two different phospholipid mix-
tures were used for the formulation of liposomes 
(Table 1). Formulations 1, 2 and 3 contained mainly 
phosphatidylcholine and phosphatidylethanolamine, 
which meant that these liposomes did not carry electrical 
charges and were mainly lipophilic. Formulation 4 
contained a large amount of negatively charged 
phospholipids resulting in electrically charged liposomes 
at physiological pH with hydrophilic characteristics. 
There was virtually no difference in particle size and 
lamellarity between the four formulations. 
Formulation 3 had a higher content of electrolytes 
than the other formulations, in which liposomes were 
fixed in a gel matrix. Liposomes in formulation 3 were 
mobile in a dispersion, since electrolytes prevent the for-
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mation of a gel matrix. The main fatty acids in the 
phospholipids were linoleic acid (75%) and linolenic acid 
(7%). The ratio of unsaturated to saturated fatty acids 
was 9:1 in all formulations. 
Formulation 2 was enriched with 10% primrose oil 
which contained 71% linoleic acid, 7% oleic acid, 10% 
y-linolenic acid, 9% palmitic acid, 1% stearic acid, and 
2% other fatty acids [2]. The ratio of unsaturated to 
saturated fatty acids was 9:1, the same as in the original 
liposomal phospholipids. In addition to the fatty acid 
composition of formulations 1, 3 and 4, with 7% a-
linolenic acid, formulation 2 contained 1% y-linolenic 
acid. 
Fresh 1% anthralin phospholipid was prepared by 
incorporation of 50 mg purified anthralin in 5 g of the 
vehicle. Purification was by column chromatography 
(Si0 2 , dichloromethane). During the time of investi-
gation the preparation was stored at 5°C under light 
protection. Samples were taken at different intervals and 
analysed by thin layer chromatography [15]. C4-lactone, 
a hydrophilic derivative of anthralin with a lacton ring 
at position 10, was synthesized as described elsewhere 
[16]. C4-lactone (derivative X) has been shown to inhibit 
cell growth in vitro more effectively and to be less toxic 
than anthralin [5]. It was therefore compared with 
anthralin, using a 1% concentration in phospholipids. 
We found that anthralin rapidly degraded in formu-
lation 2, less rapidly in formulations 1 and 3, and rela-
tively slowly in formulation 4 (Table 2). This meant that 
there was virtually no difference between the degradation 
time in the gel or the dispersion formulations 1 and 3, 
even though anthralin was less soluble in the dispersion 
than in the gel. The addition of primrose oil reduced the 
degradation time. The lowest anthralin degradation rate 
was obtained with the liposome preparation containing 
a higher content of negatively charged phospholipids. 
C4-lactone was more stable than anthralin, at least in 
formulations 2 and 3. 
The results demonstrate that anthralin is oxidized 
within days in liposomal phospholipids. The oxidation 
process is retarded by using liposomes consisting mostly 
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Table 1. Liposomal phospholipid formulations 
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Formulation 
1: N A T 8257 2: N A T 8308 3: N A T 8417 4: N A T 8418 
Phospholipid (wt%) 20 a 18a 19a 20 b 
Ethanol (wt%) 16 16 16 16 
Other ingredients (wt%) — 10% primrose oil 4% choline chloride — 
Water (wt%) to 100 to 100 to 100 to 100 
Particle size (nm) 200 + 20 200 + 20 160 + 20 190 + 20 
Lamellarity 4 - 6 4 - 6 3 - 5 2 - 4 
p H 6.5 6.1 5.7 7.1 
Physical form Transparent gel Non-transparent gel Dispersion Non-transparent gel 
a 85% PC, 10% PE, 5% acidic P L ; b 28% PC, 2% PE, 43% acidic PL , 6% Sterine and derivatives, 21% soya oil. 
Abbreviations: PL , phospholipids; PC, phosphatidylcholine; PE, phosphatidylethanolamine. Acidic P L are phosphatide acid, phosphatidyl-
inositol and N-acylphosphatidylethanolamine 
Table 2. Stability of anthralin (C4-lactone) in liposomal phospholi-
pid formulations. +, unaffected or minimally oxidized; +, highly 
degraded; —, completely oxidized; n.d., not done 
Day Formulation 
1 2 3 4 
0 + (+) + (+) + (+) + (+) 
1 + (+) + (+) + (+) + (+) 
2 + (n.d.) + (n.d.) + (n.d.) + (n.d.) 
5 + (+) ± (+) + (+) + (+) 
9 + (±) ± (±) + (+) + (+) 
23 ± (±) - ( ± ) ± (±) + (+) 
36 - (±) - (±) - ( ± ) ± ( ± ) 
of negatively charged phospholipids. Compared with 
other vehicles (Table 3) anthralin in phospholipids was 
less stable than in white soft paraffin, but more stable 
than in aqueous or acetone solutions. 
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